DTaP-IPV/Hib vaccine (Pentacel®)

Pediatric Drugs

Volumn 10, Issue 6, 2008, Pages 405-416

  Dhillon, Sohita ^a,b   Keam, Susan J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Diphtheria; Pertussis; Poliomyelitis; Tetanus

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IPOL; MEASLES MUMPS RUBELLA VACCINE; PENTACEL; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLIVAX; QUADRACEL; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BRAIN DISEASE; BRONCHIOLITIS; CLINICAL TRIAL; CRYING; DEHYDRATION; DIPHTHERIA; DRUG TOLERABILITY; FEVER; GASTROENTERITIS; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HYPOTONIC HYPORESPONSIVE EPISODE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LETHARGY; PERTUSSIS; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SEROCONVERSION; SIDE EFFECT; TETANUS;

ANTIBODY FORMATION; ANTIGENS, VIRAL; DIPHTHERIA; HAEMOPHILUS INFLUENZAE TYPE B; HUMANS; INFANT; POLIOVIRUS; TETANUS; VACCINES, COMBINED; WHOOPING COUGH;

EID: 55949107060     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/0148581-200810060-00008     Document Type: Review

References (25)

1. Centers for Disease Control and Prevention. Vaccine timeline [online]. Available from URL: http://www.cdc.gov/vaccines/pubs/vacc-timeline.htm#50years [Accessed 2008 Sep 4]
2. World Health Organization. 10 facts on immunization [online]. Available from URL: http://www.who.int/features/factfiles/immunization/en/index.html [Accessed 2008 Sep 4]
3. United Nations Children's Fund. Immunization summary: the 2007 edition [online]. Available from URL: http://www.unicef.org/publications/files/ Immunization_Summary_2007.pdf [Accessed 2008 Sep 4]
4. Sanofi Pasteur. US FDA licenses Sanofi Pasteur's new pediatric combination vaccine, Pentacel® [media release]. 2008 Jun 23
5. Centers for Disease Control and Prevention. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR 1999; 48 (No. RR-5)
6. Centers for Disease Control and Prevention. Recommended immunization schedule for persons aged 0-6 years [online]. Available from URL: http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2008/ 08_0-6yrs_s-chedule_bw_pr.pdf [Accessed 2008 Sep 4]
7. Public Health Agency of Canada. Immunization schedules [online]. Available from URL: http://www.phac-aspc.gc.ca/im/is-cv/index-eng.php#a [Accessed 2008 Sep 4]
8. Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Future Drugs 2005; 4 (6): 793-805
9. Sanofi Pasteur Inc. Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine (Pentacel): US product information [online]. Available from URL: http://www.fda.gov/cber/label/pentacelLB.pdf [Accessed 2008 Oct 17]
10. Eskola J, Olander RM, Hovi T, et al. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996 Dec 21; 348 (9043): 1688-92
11. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine 1998 Apr; 16 (6): 576-85
12. Lee CY, Thipphawong J, Huang LM, et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 1999 Jan; 103 (1): 25-30
13. Chatterjee A, Jordanov E, Klein N, et al. Comparative immunogenicity of different 5-component acellular pertussis vaccine formulations in infants [abstract no. 4464.12]. Pediatric Acedemic Societies' and Asian Society for Pediatric Research Joint Meeting; 2008 May 2-6; Honolulu (HI)
14. Scheifele DW, Bettinger JA, Halperin SA, et al. Ongoing control of haemophilus influenzae type b infections in Canadian children, 2004-2007. Pediatr Infect Dis J 2008 Aug; 27 (8): 1-2
15. Greenberg DP, Doemland ML, Lavigne P, et al. Impact of Pentacel (DTaP-IPV//PRP-T) on the epidemiology of invasive Hib disease and pertussis in Canada. The 5th Pediatric Infectious Disease Society Conference; 2005 Oct 10-11; Napa (CA)
16. Food and Drug Administration. Pentacel: immunogenicity review [online]. Available from URL: http://www.fda.gov/cber/products/pentacel/pentacel061908mem. pdf [Accessed 2008 Aug 8]
17. Food and Drug Administration. Pentacel: clinical safety review [online]. Available from URL: http://www.fda.gov/cber/products/pentacel/pentacel061308mem. pdf [Accessed 2008 Aug 8]
18. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996 Feb 8; 334 (6): 349-55
19. Noriega F, Tomovici A, Jemiolo D, et al. Safety and immunogenicity comparison of a fourth dose of DTaP-IPV//PRP-T (Pentacel™) to the separate administration of DAPTACEL® and ActHIB® [abstract no. 985]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6-9; San Francisco (CA)
20. Edwards KM, Tsang PH, Wang L, et al. Safety and immunogenicity of DTaP-IPV//PRP-T (Pentacel™) coadministered with pneumococcal conjugate vaccine (Prevnar®) at 2, 4, and 6 months of age [abstract no. 984]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6-9; San Francisco (CA)
21. Noriega F, Tsang P, Jemiolo D, et al. Immunogenicity of a four-dose series of DTaP-IPV//PRP-T (Pentacel®) [abstract no. 9]. The 5th Pediatric Infectious Disease Conference; 2005 Oct 10-11; Napa (CA)
22. Noriega F, Greenberg DP, Tsang PH, et al. Effect of pneumococcal conjugate vaccine on antibody responses to concomitantly administered Pentacel™ (DTaP-IPV//PRP-T) or licensed equivalent vaccines [abstract no. 981]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6-9; San Francisco (CA)
23. Scheifele DW, Halperin SA, Rubin E, et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b conjugate) when administered as a fourth dose at 15 to 18 months of age. Hum Vaccin 2005 Sep 31; 1 (5): 180-6
24. Sanofi Pasteur Inc.. DAPTACEL: US prescribing information [online]. Available from URL: http://www.fda.gov/cber/products/daptacel.htm [Accessed 2008 Oct 17]
25. Food and Drug Administration. Review memo (4/7/2006) [online]. Available from URL: http://www.fda.gov/cber/products/pentacel/pentacel040706mem.pdf [Accessed 2008 Oct 24]